In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
|Articles|July 18, 2011
Bracket Acquires Arrowhead for ePRO Technology
Advertisement
Bracket announced its first acquisition since launching last month. Arrowhead Electronic Healthcare, a global provider of electronic Patient-Reported Outcome (ePRO) technologies, will join Bracket. Bracket is committed to building a broad platform of technology tools to improve how pharmaceutical research and development is conducted. Handheld ePRO is a natural complement to Bracket’s existing eClinical platform.
UBC launched Bracket, a Specialty Services provider last month. Adam Butler, vice president at UBC and who is spearheading Bracket, told Applied Clinical Trials: "We formed Bracket on the premise that a comprehensive re-examination of how pharmaceutical research and development is conducted was required. I think it's clear that the combination of technology tools and clinical expertise will be a core part of how we improve R&D, and I expect to see an increasing focus on improving the way we integrate technology into these programs." For more on the Bracket launch, listen to this
As part of the Arrowhead acquisition,
· Arrowhead’s ePRO solutions will be integrated into Bracket’s existing suite of eClinical tools, including IVRS, IWRS, and e-Learning platforms.
· Arrowhead's ePRO solutions are uniquely engineered to better capture the true patient experience in clinical studies so trial sponsors can focus on making better, faster drug development decisions.
· Independent research indicates sharp increases in the adoption and use of handheld ePRO tools in clinical trials over the next two years.
· Arrowhead's ePRO-LOG™ software platform is used on smartphones, tablet computers, the Web, and text messaging applications.
Arrowhead’s trademarked technologies include:
· ePRO-LOG™ Smartphone
· Ideal for frequently administering questionnaires and when portability and alarm reminders are essential.
· ePRO-LOG™ Tablet
· Excellent for studies where content is dense, moderate portability is needed, and Internet availability is limited. ePRO-LOG™ Tablet can be deployed at site or patients' homes; many Quality of Life questionnaires are good candidates for tablet computers.
· ePRO-LOG™ Web
· ePRO-LOG™ Web works well on studies with dense content and where patients have regular access to Web sites or 3G Web-enabled phones. ePRO-LOG™ Web can be administered at home or in clinic; many Quality of Life questionnaires are good candidates for Web.
· ePRO-LOG™ SMS
· Optimal for simple data logging and alert notifications, ePRO-LOG™ SMS is highly mobile and relatively inexpensive.
Advertisement
Related to this article
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Why clinical development’s next AI bottleneck is not the model, but the system around it.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines
The pilot pairs drug sponsors with qualified research institutions to compress the path from drug identification to first-in-human study through rolling submission review and earlier coordination of institutional review board and site activation activities.
A Syneos Health-announced study from Tufts Center for the Study of Drug Development finds no single sourcing model consistently outperforms others, pointing instead to vendor coordination, governance, and fit-for-purpose design as the real performance drivers.
Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities
2
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
3
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
4
What "Patient Voice" Actually Requires: Beyond the Buzzword
5